Clinical Infectious Diseases · 2020 · 33 citations · 25 references
PharmacyPharmacoeconomicsPharmacologyCost-effectiveness AnalysisPharmacogeneticsPharmacogenomicsCost-effectiveness ModelingDose OptimizationDrug EvaluationPharmaceutical EconomicsPharmacoeconomic EvaluationTuberculosis PharmacotherapyActive Tuberculosis TreatmentCost-effectivenessHealth Outcomes AnalysisInterindividual Pharmacokinetic VariabilityN-acetyltransferase 2 PolymorphismPharmacogenomic VariationPharmacogenomic-guided DosingTuberculosis Drug Resistance
BACKGROUND: There is marked interindividual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosis treatment. For isoniazid, mutations in the N-acetyltransferase 2 (NAT2) gene explain >88% of pharmacokinetic variability. However, weight-based dosing remains the norm globally. The potential clinical impact and cost-effectiveness of pharmacogenomic-guided therapy (PGT) are unknown. METHODS: We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India. PGT was modeled to reduce isoniazid toxicity among slow NAT2 acetylators and reduce treatment failure among rapid acetylators. The genotyping test was assumed to cost the same as the GeneXpert test. The main outcomes were costs (2018 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS: In Brazil, PGT gained 19 discounted life-years (23 QALYs) and cost $11 064 per 1000 patients, a value of $476 per QALY gained. In South Africa, PGT gained 15 life-years (19 QALYs) and cost $33 182 per 1000 patients, a value of $1780 per QALY gained. In India, PGT gained 20 life-years (24 QALYs) and cost $13 195 per 1000 patients, a value of $546 per QALY gained. One-way sensitivity analyses showed the cost-effectiveness to be robust to all input parameters. Probabilistic sensitivity analyses were below per capita gross domestic product in all 3 countries in 99% of simulations. CONCLUSIONS: Isoniazid PGT improves health outcomes and would be cost-effective in the treatment of drug-susceptible tuberculosis in Brazil, South Africa, and India.
25
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Global tuberculosis report (2014)
L.A. Gabbasova, E.R. Experts Who · 2014 · 13.2K citations
Disability weights for the Global Burden of Disease 2013 study
Joshua A. Salomon, Juanita A. Haagsma, Adrian Davis et al. · The Lancet Global Health · 2015 · 1.2K citations · Full text
Junichi Azuma, Masako Ohno, Ryuji Kubota et al. · European Journal of Clinical Pharmacology · 2012 · 273 citations · Full text